Angiotech and former president & CEO William Hunter reach an agreement in principle following a year-long severance package dispute.

Angiotech Pharmaceuticals reached an agreement in principal with former president & CEO William Hunter to settle a matter regarding Hunter's termination payments, with Hunter receiving more than double the company's initial cash offer.

Hunter signed on with Angiotech in April 2004 and was terminated October 17, 2011, resigning from the company's board of directors shortly thereafter. He was succeeded by then-CFO Thomas Bailey, who still holds the corner office.